KB-1283

Bemarituzumab

Background

Bemarituzumab, also named FPA-144, is a recombinant IgG1 kappa, human monoclonal antibody produced in CHO cell culture, which can selective bind to FGFR2b. Bemarituzumab is a first-in-class targeted antibody that blocks fibroblast growth factors (FGFs) from binding and activating FGFR2b, inhibiting several downstream pathways. Blocking FGFR2b activation is thought to slow cancer progression. Bemarituzumab is being developed in gastric and GEJ cancer as a targeted therapy for tumors that overexpress FGFR2b.

Specifications

Catalog Number:
KB-1283
Cell Line Name:
Bemarituzumab
Price:
0
Host Cell Line:
EXPI-CHO
Target:
FGFR2b
Species Reactivity:
Human
Application:
ELISA
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA

References

1.Gemo AT, Deshpande AM, Palencia S, et al: FPA144: A therapeutic antibody for treating patients with gastric cancers bearing FGFR2 gene amplification. Cancer Res 74, 2014 .
Please enable JavaScript in your browser to complete this form.